Edition:
India

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

11.33USD
22 Nov 2017
Change (% chg)

$0.12 (+1.07%)
Prev Close
$11.21
Open
$11.21
Day's High
$11.45
Day's Low
$10.97
Volume
530,688
Avg. Vol
931,412
52-wk High
$13.38
52-wk Low
$6.74

Select another date:

Mon, Nov 13 2017

BRIEF-Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting

* Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting

BRIEF-ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

BRIEF-Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

* Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel

* Array Biopharma appoints Curtis Oltmans as general counsel Source text for Eikon: Further company coverage:

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

BRIEF-Amgen and Array BioPharma announce preclinical license and collaboration agreement

* Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

BRIEF-Array Biopharma submits new drug applications to FDA

* Array Biopharma submits new drug applications to FDA for binimetinib and encorafenib in advanced melanoma

BRIEF-Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor

* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and South Korea.

BRIEF-Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds

* Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib

Select another date: